{
    "2019-05-24": [
        [
            {
                "time": "",
                "original_text": "投入需加强？ A股年入50亿药企仅4家研发占收入比超10%",
                "features": {
                    "keywords": [
                        "研发投入",
                        "A股",
                        "药企",
                        "收入占比"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "一致性评价：又一品种3家满员16种获承办 科伦药业添新丁",
                "features": {
                    "keywords": [
                        "一致性评价",
                        "科伦药业",
                        "品种获批"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "科创板估值系列报告： 节能环保及医药生物行业估值分析",
                "features": {
                    "keywords": [
                        "科创板",
                        "估值分析",
                        "节能环保",
                        "医药生物"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "环保"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "步长制药销售费用占营收59%低于同行水平 商誉两年未减少转型大健康",
                "features": {
                    "keywords": [
                        "步长制药",
                        "销售费用",
                        "商誉",
                        "大健康"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-05-23",
                "original_text": "格隆汇港股通5日资金流入流出排行榜 | 5月23日",
                "features": {
                    "keywords": [
                        "港股通",
                        "资金流向",
                        "排行榜"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}